Bill Sponsor
Senate Bill 1334
117th Congress(2021-2022)
PFAS Accountability Act of 2021
Introduced
Introduced
Introduced in Senate on Apr 22, 2021
Overview
Text
Introduced
Apr 22, 2021
Latest Action
Apr 22, 2021
Origin Chamber
Senate
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
1334
Congress
117
Policy Area
Environmental Protection
Environmental Protection
Primary focus of measure is regulation of pollution including from hazardous substances and radioactive releases; climate change and greenhouse gases; environmental assessment and research; solid waste and recycling; ecology. Measures concerning energy exploration, efficiency, and conservation may fall under Energy policy area.
Sponsorship by Party
Democrat
New York
Democrat
New Hampshire
Democrat
Wisconsin
Senate Votes (0)
House Votes (0)
No Senate votes have been held for this bill.
Summary

PFAS Accountability Act of 2021

This bill provides a cause of action under the Toxic Substances Control Act for individuals or classes of individuals who were significantly exposed to perfluoroalkyl or polyfluoroalkyl substances, commonly referred to as PFAS. These substances are man-made and may have adverse human health effects. A variety of products contain the compounds, such as nonstick cookware or weatherproof clothing.

Specifically, the bill provides a cause of action those who were significantly exposed to PFAS (or have reasonable grounds to believe they were exposed) against persons who engaged in any portion of a manufacturing process that created the PFAS and foresaw (or reasonably should have foreseen) the creation or use of PFAS would result in human exposure.

The bill authorizes a court to award medical monitoring to claimants if (1) they have been significantly exposed to PFAS, (2) they have an increased risk of developing a disease associated with such exposure, (3) the increased risk provides a reasonable basis to conclude that periodic diagnostic medical examinations is necessary, and (4) the medical examinations are effective in detecting a disease associated with PFAS exposure.

The bill establishes a presumption of significant exposure to PFAS if the claimant (1) provides medical results proving the presence of PFAS in the body, or (2) demonstrates the defendant's manufacturing process created the PFAS to which the claimant was exposed and the PFAS were released into one or more areas where the claimant would have been exposed for at least one year.

Text (1)
April 22, 2021
Actions (2)
04/22/2021
Read twice and referred to the Committee on Environment and Public Works.
04/22/2021
Introduced in Senate
Public Record
Record Updated
Jan 11, 2023 1:49:12 PM